帕布昔利布雜質(zhì)23
| 中文名稱 | 帕布昔利布雜質(zhì)23 |
|---|---|
| 中文同義詞 | 4-[6-[(6-溴-8-環(huán)戊基-7,8-二氫-5-甲基-7-氧代吡啶并[2,3-D]嘧啶-2-基)氨基]-3-吡啶基]-1-哌嗪羧酸叔丁酯;4-[6-[(6-溴-8-環(huán)戊基-7,8-二氫-5-甲基-7-氧代吡啶并[2,3-D]嘧啶-2-基)氨基]-3-吡啶;帕布昔利布中間體1;4-[6-[(6-溴-8-環(huán)戊基-7,8-二氫-5-甲基-7-氧代吡啶并[2,3-D]嘧啶-2-基)氨基]-3-吡啶基]-1-哌嗪羧酸叔丁酯 哌泊塞克雷布中間體 1KG;4-[6-(6-溴-8-環(huán)戊基-5-甲基-7-氧代-7,8-二氫吡啶并[2,3-D]嘧啶- 2-基氨基)-吡啶-3-基]-哌嗪-1-羧酸叔丁酯;帕布昔利布中間體6;(3E)-1-(2-氯乙酰基)-2,3-二氫-3-(甲氧基苯基亞甲基)-2-氧代-1H-吲哚-6-羧酸甲酯;帕布昔利布中間體一 |
| 英文名稱 | tert-Butyl 4-(6-(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido(2,3-d)pyrimidin-2-ylamino)-pyridin-3-yl)-piperazine-1-carboxylate |
| 英文同義詞 | 4-[6-(6-BROMO-8-CYCLOPENTYL-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO)-PYRIDIN-3-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Piperazinecarboxylic acid, 4-[6-[(6-broMo-8-cyclopentyl-7,8-dihydro-5-Methyl-7-oxopyrido[2,3-d]pyriMidin-2-yl)aMino]-3-pyridinyl]-, 1,1-diMethylethyl ester;tert-butyl 4-{6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl}piperazine-1-carboxylat;tert-butyl 4-[6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylate;tert-Butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl);Palbociclib Intermediate 4;Palbociclib-016;tert-butyl 4-[6-({6-bromo-8-cyclopentyl-5-methyl-7-oxo-7H,8H-pyrido[2,3-d]pyrimidin-2-yl}amino)pyrid |
| CAS號 | 571188-82-4 |
| 分子式 | C27H34BrN7O3 |
| 分子量 | 584.51 |
| EINECS號 | 1592732-453-0 |
| 相關(guān)類別 | 帕博西布中間體;帕博西尼中間體;帕布昔利布中間體;醫(yī)藥中間體;科研精品試劑;日用化學(xué)品;Palbociclib;PD 0332991;Anticancer;對照品-雜質(zhì)對照品;雜質(zhì)對照品 |
| Mol文件 | Mol File |
| 結(jié)構(gòu)式 |  |
帕布昔利布雜質(zhì)23 性質(zhì)
| 熔點 | >250℃ |
|---|---|
| 沸點 | 720.0±70.0 °C(Predicted) |
| 密度 | 1.439±0.06 g/cm3(Predicted) |
| 儲存條件 | 2-8°C(protect from light) |
| 酸度系數(shù)(pKa) | 5.24±0.10(Predicted) |
| 外觀 | 淺黃色至黃色固體 |
| InChIKey | UTSOLZWQDXJQRH-UHFFFAOYSA-N |
| SMILES | N1(C(OC(C)(C)C)=O)CCN(C2=CC=C(NC3=NC=C4C(C)=C(Br)C(=O)N(C5CCCC5)C4=N3)N=C2)CC1 |
帕布昔利布雜質(zhì)23是帕布昔利的雜質(zhì)，是輝瑞公司開發(fā)的治療乳腺癌的實驗藥物。它是細(xì)胞周期素依賴性激酶CDK4和CDK6的選擇性抑制劑。此外，它衍生自6-溴-2-氯-8-環(huán)戊基-5-甲基吡啶-[2,3-d]嘧啶-7（8H）-酮, 用于制備吡啶基[2,3-d]嘧啶-7（8H）-酮衍生物，作為CDK4和/或用于治療疾病的CDK6抑制劑。